Exosurf Neonatal and Survanta for Treatment of Respiratory Distress Syndrome

Completed · Phase 2/Phase 3

Conditions studied: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Bronchopulmonary Dysplasia

In brief

The purpose of this study is to compare the efficacy of two surfactants, Exosurf Neonatal (Burroughs Wellcome Co.) and Survanta (Ross Laboratories), for the treatment of neonatal respiratory distress syndrome.

Key facts

Study ID: NCT01203358
Run by: NICHD Neonatal Research Network
People needed: 617
Starts: 1991-01-01
Expected to finish: 1992-01-01
Last updated by the study team: 2019-03-22

Who can join

Age: any, up to 0. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Newborn infants weighing 501 to 1500 gm with respiratory distress syndrome were receiving assisted ventilation with 30% oxygen or more

You may not qualify if…

Less than 6 hours of age

Where it is running

Stanford University — Palo Alto, California, United States
Yale University — New Haven, Connecticut, United States
George Washington University — Washington D.C., District of Columbia, United States
University of Miami — Miami, Florida, United States
Emory University — Atlanta, Georgia, United States
Indiana University — Indianapolis, Indiana, United States
Wayne State University — Detroit, Michigan, United States
University of New Mexico — Albuquerque, New Mexico, United States
Cincinnati Children's Medical Center — Cincinnati, Ohio, United States
Case Western Reserve University, Rainbow Babies and Children's Hospital — Cleveland, Ohio, United States
University of Tennessee — Memphis, Tennessee, United States
University of Texas Southwestern Medical Center at Dallas — Dallas, Texas, United States
University of Vermont — Burlington, Vermont, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.